Diagnostic and prognostic epigenetic biomarkers in cancer

Epigenomics

Volumn 7, Issue 6, 2015, Pages 1003-1015

  Costa Pinheiro, Pedro ^a   Montezuma, Diana ^a   Henrique, Rui ^a,b   Jerónimo, Carmen ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

bladder; breast; cancer; colorectal; diagnostic prognostic biomarkers; epigenetics; kidney; lung; prostate

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BLADDER CANCER; BODY FLUID; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; COLORECTAL CANCER; EPIGENETICS; HUMAN; KIDNEY CANCER; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; CPG ISLAND; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MALE; MORTALITY; NEOPLASMS; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS; PROGNOSIS;

EID: 84947549210     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.56     Document Type: Review

References (134)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
2. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: The next generation of prostate cancer biomarkers. Sci. Transl. Med. 4(127), 127rv123 (2012).
3. Mcshane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur. J. Cancer 41(12), 1690-1696 (2005).
4. Sidransky D. Emerging molecular markers of cancer. Nat. Rev. Cancer 2(3), 210-219 (2002).
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003).
6. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate 72(11), 1248-1261 (2012).
7. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (5),E359-E386 (2015).
8. Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, Deliveliotis C. The novel prostate cancer antigen 3 (PCA3) biomarker. Int. Braz. J. Urol. 36(6), 665-668; discussion 669 (2010).
9. Baden J, Green G, Painter J et al. Multicenter evaluation of an investigational prostate cancer methylation assay. J. Urol. 182(3), 1186-1193 (2009).
10. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 374(9685), 239-249 (2009).
11. Jung M, Mollenkopf HJ, Grimm C et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med. 13(9B), 3918-3928 (2009).
12. Hoque MO, Begum S, Topaloglu O et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 64(15), 5511-5517 (2004).
13. Dietrich D, Kneip C, Raji O et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int. J. Oncol. 40(3), 825-832 (2012).
14. Hennessey PT, Sanford T, Choudhary A et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS ONE 7(2), e32307 (2012).
15. Kloten V, Becker B, Winner K et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 15(1), R4 (2013).
16. Rawson JB, Bapat B. Epigenetic biomarkers in colorectal cancer diagnostics. Expert Rev. Mol. Diagn. 12(5), 499-509 (2012).
17. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 8(12), 686-700 (2011).
18. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9-29 (2014).
19. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat. Rev. Urol. 10(1), 38-48 (2013).
20. Costa-Pinheiro P, Patel HR, Henrique R, Jeronimo C. Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer. Expert Rev. Anticancer Ther. 14(11), 1349-1358 (2014).
21. Martin SK, Vaughan TB, Atkinson T, Zhu H, Kyprianou N. Emerging biomarkers of prostate cancer (review). Oncol. Rep. 28(2), 409-417 (2012).
22. Sardana G, Diamandis EP. Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomark. Med. 6(5), 587-596 (2012).
23. Auprich M, Bjartell A, Chun FK et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur. Urol. 60(5), 1045-1054 (2011).
24. Bryant RJ, Pawlowski T, Catto JW et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106(4), 768-774 (2012).
25. Cairns P, Esteller M, Herman JG et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7(9), 2727-2730 (2001).
26. Goessl C, Muller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58(3), 335-338 (2001).
27. Jeronimo C, Usadel H, Henrique R et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60(6), 1131-1135 (2002).
28. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 9(7), 2673-2677 (2003).
29. Roupret M, Hupertan V, Yates DR et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res. 13(6), 1720-1725 (2007).
30. Jeronimo C, Henrique R, Hoque MO et al. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 10(24), 8472-8478 (2004).
31. Ellinger J, Haan K, Heukamp LC et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68(1), 42-49 (2008).
32. Baden J, Adams S, Astacio T et al. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J. Urol. 186(5), 2101-2106 (2011).
33. Partin AW, Van Neste L, Klein EA et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J. Urol.192(4), 1081-1087 (2014).
34. Ellinger J, Kahl P, Von Der Gathen J et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 70(1), 61-69 (2010).
35. Durand X, Xylinas E, Radulescu C et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int. 110(1), 43-49 (2012).
36. Kuner R, Brase JC, Sultmann H, Wuttig D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 59(1), 132-137 (2013).
37. Schaefer A, Jung M, Mollenkopf HJ et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 126(5), 1166-1176 (2010).
38. Leite KR, Tomiyama A, Reis ST et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J. Urol. 185(3), 1118-1122 (2011).
39. Spahn M, Kneitz S, Scholz CJ et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer 127(2), 394-403 (2010).
40. Li J, Fan QH, Fan XS, Zhou W, Qiu Y, Qiu L. EZH2 expression in human prostate cancer and its clinicopathologic significance. Zhonghua Nan Ke Xue 16(2), 123-128 (2010).
41. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl Cancer Inst. 95(9), 661-668 (2003).
42. Vieira FQ, Costa-Pinheiro P, Ramalho-Carvalho J et al. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocr. Relat. Cancer 21(1), 51-61 (2014).
43. Bastian PJ, Palapattu GS, Lin X et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 11(11), 4037-4043 (2005).
44. Woodson K, O'Reilly KJ, Ward DE et al. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 1(4), 183-186 (2006).
45. Weiss G, Cottrell S, Distler J et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J. Urol. 181(4), 1678-1685 (2009).
46. Henrique R, Ribeiro FR, Fonseca D et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin. Cancer Res. 13(20), 6122-6129 (2007).
47. Oliveira AI, Jeronimo C, Henrique R. Moving forward in bladder cancer detection and diagnosis: The role of epigenetic biomarkers. Expert Rev. Mol. Diagn. 12(8), 871-878 (2012).
48. Costa VL, Henrique R, Danielsen SA et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res. 16(23), 5842-5851 (2010).
49. Ellinger J, Bachmann A, Goke F et al. Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer. Urol. Int. 93(1), 113-118 (2014).
50. Zhang DZ, Lau KM, Chan ES et al. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS ONE 9(7), e100793 (2014).
51. Wang H, Albadine R, Magheli A et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol. Oncol. 30(4), 428-433 (2012).
52. Santos M, Martinez-Fernandez M, Duenas M et al. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer. Cancer Res. 74(22), 6565-6577 (2014).
53. Maher ER. Genomics and epigenomics of renal cell carcinoma. Semin. Cancer Biol. 23(1), 10-17 (2013).
54. Moch H. An overview of renal cell cancer: pathology and genetics. Semin. Cancer Biol. 23(1), 3-9 (2013).
55. Costa VL, Henrique R, Ribeiro FR et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 7, 133 (2007).
56. Silva-Santos RM, Costa-Pinheiro P, Luis A et al. MicroRNA profile: A promising ancillary tool for accurate renal cell tumour diagnosis. Br. J. Cancer 109(10), 2646-2653 (2013).
57. Urakami S, Shiina H, Enokida H et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin. Cancer Res. 12(23), 6989-6997 (2006).
58. Peters I, Rehmet K, Wilke N et al. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol. Cancer 6, 49 (2007).
59. Seligson DB, Horvath S, Mcbrian MA et al. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174(5), 1619-1628 (2009).
60. Mosashvilli D, Kahl P, Mertens C et al. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 101(12), 2664-2669 (2010).
61. Ellinger J, Kahl P, Mertens C et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int. J. Cancer 127(10), 2360-2366 (2010).
62. CAGEKID. www.cng.fr/cagekid
63. EuroTARGET. www.eurotargetproject.eu
64. Cancer Network. Recurrence score validated in clear cell RCC. www.cancernetwork.com
65. PREDICT Consortium. www.predictconsortium.eu
66. Vasudev NS, Selby PJ, Banks RE. Renal cancer biomarkers: The promise of personalized care. BMC Med. 10, 112 (2012).
67. Ganti AK, Mulshine JL. Lung cancer screening: panacea or pipe dream? Ann. Oncol. 16(Suppl. 2), ii215-ii219 (2005).
68. Belinsky SA, Nikula KJ, Palmisano WA et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95(20), 11891-11896 (1998).
69. Topaloglu O, Hoque MO, Tokumaru Y et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin. Cancer Res. 10(7), 2284-2288 (2004).
70. Van Der Drift MA, Prinsen CF, Knuiman GJ, Janssen JP, Dekhuijzen PN, Thunnissen FB. Diagnosing peripheral lung cancer: The additional value of the Ras-association domain family 1A gene methylation and Kirsten rat sarcoma 2 viral oncogene homolog mutation analyses in washings in nondiagnostic bronchoscopy. Chest 141(1), 169-175 (2012).
71. Kneip C, Schmidt B, Seegebarth A et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 6(10), 1632-1638 (2011).
72. Ilse P, Biesterfeld S, Pomjanski N, Wrobel C, Schramm M. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis. Cancer Genomics Proteomics 11(5), 251-258 (2014).
73. Usadel H, Brabender J, Danenberg KD et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62(2), 371-375 (2002).
74. Walter K, Holcomb T, Januario T et al. Discovery and development of DNA methylation-based biomarkers for lung cancer. Epigenomics 6(1), 59-72 (2014).
75. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 23(8), 1157-1164 (2010).
76. Yu L, Todd NW, Xing L et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 127(12), 2870-2878 (2010).
77. Gilad S, Lithwick-Yanai G, Barshack I et al. Classification of the four main types of lung cancer using a microRNAbased diagnostic assay. J. Mol. Diagn. 14(5), 510-517 (2012).
78. Van Den Broeck A, Brambilla E, Moro-Sibilot D et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin. Cancer Res. 14(22), 7237-7245 (2008).
79. Brock MV, Hooker CM, Ota-Machida E et al. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 358(11), 1118-1128 (2008).
80. Zhang Y, Wang R, Song H et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett. 303(1), 21-28 (2011).
81. Cai J, Wu J, Zhang H et al. miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res. 73(2), 756-766 (2013).
82. Cao J, Song Y, Bi N et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 73(11), 3326-3335 (2013).
83. Bi N, Cao J, Song Y et al. A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy. PLoS ONE 9(3), e91388 (2014).
84. Li M, Zhang Q, Wu L et al. Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer. Oncol. Rep. 31(4), 1961-1967 (2014).
85. Landi MT, Zhao Y, Rotunno M et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 16(2), 430-441 (2010).
86. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res. 70(1), 36-45 (2010).
87. Bartling B, Hofmann HS, Boettger T et al. Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 49(2), 145-154 (2005).
88. Minamiya Y, Ono T, Saito H et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 74(2), 300-304 (2011).
89. Matthaios D, Hountis P, Karakitsos P, Bouros D, Kakolyris S. H2AX a promising biomarker for lung cancer: A review. Cancer Invest. 31(9), 582-599 (2013).
90. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92(7), 564-569 (2000).
91. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 8(4), R38 (2006).
92. Lo PK, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 9(12), 1879-1902 (2008).
93. Muggerud AA, Ronneberg JA, Warnberg F et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 12(1), R3 (2010).
94. Karsli-Ceppioglu S, Dagdemir A, Judes G et al. Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics 6(6), 651-664 (2014).
95. Jeronimo C, Monteiro P, Henrique R et al. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res. Treat. 109(1), 27-34 (2008).
96. Melnikov AA, Scholtens DM, Wiley EL, Khan SA, Levenson VV. Array-based multiplex analysis of DNA methylation in breast cancer tissues. J. Mol. Diagn. 10(1), 93-101 (2008).
97. Fox BP, Kandpal RP. DNA-based assay for EPHB6 expression in breast carcinoma cells as a potential diagnostic test for detecting tumor cells in circulation. Cancer Genom. Proteomics 7(1), 9-16 (2010).
98. Xu Z, Bolick SC, Deroo LA, Weinberg CR, Sandler DP, Taylor JA. Epigenome-wide association study of breast cancer using prospectively collected sister study samples. J. Natl Cancer Inst. 105(10), 694-700 (2013).
99. Severi G, Southey MC, English DR et al. Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer. Breast Cancer Res. Treat. 148(3), 665-673 (2014).
100. The sister study. A study of the environmental and genetic risk factors for breast cancer. http://sisterstudy.niehs.nih.gov
101. Godfrey AC, Xu Z, Weinberg CR et al. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 15(3), R42 (2013).
102. Hu Z, Dong J, Wang LE et al. Serum microRNA profiling and breast cancer risk: The use of miR-484/191 as endogenous controls. Carcinogenesis 33(4), 828-834 (2012).
103. Wu Q, Wang C, Lu Z, Guo L, Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin. Chim. Acta 413(13-14), 1058-1065 (2012).
104. Kodahl AR, Zeuthen P, Binder H, Knoop AS, Ditzel HJ. Alterations in circulating miRNA levels following early-stage estrogen receptor-positive breast cancer resection in postmenopausal women. PLoS ONE 9(7), e101950 (2014).
105. Dalvai M, Bystricky K. The role of histone modifications and variants in regulating gene expression in breast cancer. J. Mammary Gland Biol. Neoplasia 15(1), 19-33 (2010).
106. Stefansson OA, Esteller M. Epigenetic modifications in breast cancer and their role in personalized medicine. Am. J. Pathol. 183(4), 1052-1063 (2013).
107. Muller HM, Widschwendter A, Fiegl H et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 63(22), 7641-7645 (2003).
108. Martins AT, Monteiro P, Ramalho-Carvalho J et al. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res. Treat. 129(1), 1-9 (2011).
109. Maier S, Nimmrich I, Koenig T et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifentreated, node-negative breast cancer patients-technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur. J. Cancer 43(11), 1679-1686 (2007).
110. Goebel G, Berger R, Strasak AM et al. Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Br. J. Cancer 106(1), 189-198 (2012).
111. Martens JW, Nimmrich I, Koenig T et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 65(10), 4101-4117 (2005).
112. Gasparini P, Cascione L, Fassan M et al. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 5(5), 1174-1184 (2014).
113. Marino AL, Evangelista AF, Vieira RA et al. MicroRNA expression as risk biomarker of breast cancer metastasis: A pilot retrospective case-cohort study. BMC Cancer 14, 739 (2014).
114. Elsheikh SE, Green AR, Rakha EA et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 69(9), 3802-3809 (2009).
115. Rangasamy D. Histone variant H2A.Z can serve as a new target for breast cancer therapy. Curr. Med. Chem. 17(28), 3155-3161 (2010).
116. Van Engeland M, Derks S, Smits KM, Meijer GA, Herman JG. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol. 29(10), 1382-1391 (2011).
117. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 29(1), 181-206 (2010).
118. Coppede F, Lopomo A, Spisni R, Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J. Gastroenterol. 20(4), 943-956 (2014).
119. Chen WD, Han ZJ, Skoletsky J et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst. 97(15), 1124-1132 (2005).
120. Grutzmann R, Molnar B, Pilarsky C et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 3(11), e3759 (2008).
121. Payne SR. From discovery to the clinic: The novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Epigenomics 2(4), 575-585 (2010).
122. Summers T, Langan RC, Nissan A et al. Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J. Cancer 4(3), 210-216 (2013).
123. Church TR, Wandell M, Lofton-Day C et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63(2), 317-325 (2014).
124. Connolly D, Yang Z, Castaldi M et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res. 13(4), R76 (2011).
125. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 371(2), 187-188 (2014).
126. Baba Y, Huttenhower C, Nosho K et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol. Cancer 9, 125 (2010).
127. Antelo M, Balaguer F, Shia J et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS ONE 7(9), e45357 (2012).
128. Nilsson TK, Lof-Ohlin ZM, Sun XF. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Int. J. Oncol. 42(1), 127-133 (2013).
129. Nagasaka T, Sharp GB, Notohara K et al. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin. Cancer Res. 9(14), 5306-5312 (2003).
130. Jensen LH, Rasmussen AA, Byriel L et al. Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: A descriptive and prognostic cancer marker study. Cell Oncol. (Dordr) 36(5), 411-419 (2013).
131. Kamimae S, Yamamoto E, Yamano HO et al. Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors. Cancer Prev. Res. (Phila.) 4(5), 674-683 (2011).
132. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4), 425-436 (2008).
133. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 79(3-4), 313-320 (2010).
134. Chang KH, Miller N, Kheirelseid EA et al. MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur. J. Surg. Oncol. 37(7), 597-603 (2011).